Vcanbio Cell & Gene Engineering Past Earnings Performance
Past criteria checks 1/6
Vcanbio Cell & Gene Engineering has been growing earnings at an average annual rate of 46.2%, while the Biotechs industry saw earnings growing at 8.9% annually. Revenues have been growing at an average rate of 4.4% per year. Vcanbio Cell & Gene Engineering's return on equity is 2.8%, and it has net margins of 6.8%.
Key information
46.2%
Earnings growth rate
47.0%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | 4.4% |
| Return on equity | 2.8% |
| Net Margin | 6.8% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Vcanbio Cell & Gene Engineering makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 1,610 | 109 | 724 | 195 |
| 31 Dec 23 | 1,590 | 106 | 725 | 184 |
| 30 Sep 23 | 1,581 | 131 | 724 | 154 |
| 30 Jun 23 | 1,584 | 131 | 739 | 154 |
| 31 Mar 23 | 1,538 | 115 | 734 | 150 |
| 31 Dec 22 | 1,555 | 113 | 738 | 146 |
| 30 Sep 22 | 1,552 | 79 | 794 | 141 |
| 30 Jun 22 | 1,536 | 109 | 793 | 128 |
| 31 Mar 22 | 1,563 | 146 | 793 | 133 |
| 31 Dec 21 | 1,535 | 155 | 787 | 134 |
| 30 Sep 21 | 1,509 | -69 | 753 | 121 |
| 30 Jun 21 | 1,467 | -97 | 715 | 127 |
| 31 Mar 21 | 1,409 | -87 | 687 | 114 |
| 31 Dec 20 | 1,319 | -127 | 647 | 112 |
| 30 Sep 20 | 1,351 | 89 | 618 | 125 |
| 30 Jun 20 | 1,338 | 68 | 624 | 113 |
| 31 Mar 20 | 1,342 | 25 | 633 | 112 |
| 31 Dec 19 | 1,387 | 50 | 635 | 108 |
| 30 Sep 19 | 1,355 | -182 | 676 | 115 |
| 30 Jun 19 | 1,345 | -189 | 692 | 109 |
| 31 Mar 19 | 1,320 | -43 | 693 | 103 |
| 31 Dec 18 | 1,321 | 59 | 707 | 101 |
| 30 Sep 18 | 1,333 | 317 | 676 | 84 |
| 30 Jun 18 | 1,327 | 322 | 652 | 91 |
| 31 Mar 18 | 1,434 | 116 | 703 | 124 |
| 31 Dec 17 | 1,321 | 10 | 673 | 102 |
| 30 Sep 17 | 1,238 | 60 | 629 | 80 |
| 30 Jun 17 | 1,113 | 22 | 579 | 52 |
| 31 Mar 17 | 876 | 72 | 461 | 0 |
| 31 Dec 16 | 838 | 38 | 423 | 0 |
| 30 Sep 16 | 768 | 130 | 375 | 0 |
| 30 Jun 16 | 740 | -64 | 362 | 0 |
| 31 Mar 16 | 721 | 41 | 351 | 0 |
| 31 Dec 15 | 709 | 208 | 353 | 0 |
| 30 Sep 15 | 676 | 69 | 360 | 0 |
| 30 Jun 15 | 615 | 305 | 340 | 0 |
| 31 Mar 15 | 544 | 188 | 307 | 0 |
| 31 Dec 14 | 477 | 35 | 287 | 0 |
| 30 Sep 14 | 400 | 57 | 247 | 0 |
| 30 Jun 14 | 389 | 29 | 238 | 0 |
| 31 Mar 14 | 383 | 23 | 246 | 0 |
| 31 Dec 13 | 361 | 7 | 242 | 0 |
| 30 Sep 13 | 353 | -3 | 250 | 0 |
| 30 Jun 13 | 337 | -3 | 239 | 0 |
Quality Earnings: 600645 has a large one-off loss of CN¥38.4M impacting its last 12 months of financial results to 31st March, 2024.
Growing Profit Margin: 600645's current net profit margins (6.8%) are lower than last year (7.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 600645 has become profitable over the past 5 years, growing earnings by 46.2% per year.
Accelerating Growth: 600645's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 600645 had negative earnings growth (-4.6%) over the past year, making it difficult to compare to the Biotechs industry average (-3.2%).
Return on Equity
High ROE: 600645's Return on Equity (2.8%) is considered low.